Literature DB >> 1668886

Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses.

P M Howley1, K Münger, H Romanczuk, M Scheffner, J M Huibregtse.   

Abstract

Insight into the mechanisms by which DNA tumor viruses transform cells has come from the recognition that the virus-encoded oncoproteins interact specifically with important cell regulatory proteins. The "high risk" human papillomaviruses such as HPV-16 and HPV-18 which are associated with human anogenital carcinomas encode two transforming genes (E6 and E7) which are expressed in HPV positive cancers and derived cell lines. E7 shares functional and structural features with the adenovirus E1A proteins. Like Ad E1A and the large T proteins of the polyomaviruses, E7 can complex pRB. The E7 proteins of the "high risk" HPVs associate with pRB with approximately a 10-fold higher affinity than do the E7 proteins of the "low risk" HPVs, and important biological differences between the E7 proteins of these two groups of HPVs are determined by amino-terminal sequences which include the pRB binding domain. Like SV40 large T and Ad 5 E1B, the E6 oncoprotein encoded by the "high risk" HPVs can form a complex with p53. In vitro, E6 promotes the degradation of p53 and this degradation involves the ubiquitin-dependent protease system. The selective degradation of cellular proteins such as p53 with negative regulatory functions provides a novel mechanism of action for dominant acting oncoproteins. The relevance of the inactivation of the normal functions of pRB and p53 in human cervical carcinogenesis has recently been demonstrated by the analysis of these two genes and their products in a series of HPV-positive and HPV-negative cell lines. Each of five HPV-positive cervical cancer cell lines expressed normal pRB and low levels of wild type p53 proteins, which are presumed to be altered in function as a consequence of association with the HPV oncoproteins. In contrast, mutations were identified in the p53 and RB genes expressed in the HPV-negative cervical carcinoma cell lines, C33-A and HT-3. These results support the hypothesis that the inactivation of the normal functions of the tumor suppressor proteins pRB and p53 are important steps in human cervical carcinogenesis, either by mutation or through complex formation with HPV E6 and E7 oncoproteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1668886

Source DB:  PubMed          Journal:  Princess Takamatsu Symp


  16 in total

1.  Transformation by bovine papillomavirus type 1 E6 is independent of transcriptional activation by E6.

Authors:  R Ned; S Allen; S Vande Pol
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

2.  Inhibition of p53 tumor suppressor by viral interferon regulatory factor.

Authors:  H Nakamura; M Li; J Zarycki; J U Jung
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Genetic analysis of high-risk e6 in episomal maintenance of human papillomavirus genomes in primary human keratinocytes.

Authors:  Regina B Park; Elliot J Androphy
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  The human papillomavirus 16 E6 protein can either protect or further sensitize cells to TNF: effect of dose.

Authors:  M Filippova; T A Brown-Bryan; C A Casiano; P J Duerksen-Hughes
Journal:  Cell Death Differ       Date:  2005-06-03       Impact factor: 15.828

5.  The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.

Authors:  H Zimmermann; R Degenkolbe; H U Bernard; M J O'Connor
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Inhibition of human papilloma virus E2 DNA binding protein by covalently linked polyamides.

Authors:  Thomas D Schaal; William G Mallet; Dustin L McMinn; Nam V Nguyen; Michelle M Sopko; Sam John; Bhavin S Parekh
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

Review 7.  Immunotherapy for cervical cancer: Research status and clinical potential.

Authors:  Jun-Han Su; Anjui Wu; Elizabeth Scotney; Barbara Ma; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  BioDrugs       Date:  2010-04-01       Impact factor: 5.807

8.  HPV16 E6*II gene expression in intraepithelial cervical lesions as an indicator of neoplastic grade: a pilot study.

Authors:  Dorota Pastuszak-Lewandoska; Anna Bartosińska-Dyc; Monika Migdalska-Sęk; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska; Krzysztof Szyłło; Ewa Brzeziańska
Journal:  Med Oncol       Date:  2014-01-17       Impact factor: 3.064

9.  Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis.

Authors:  Maria Filippova; Valery A Filippov; Mercy Kagoda; Theodore Garnett; Nadya Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

10.  A genetic strategy to overcome the senescence of primary meningioma cell cultures.

Authors:  Gilson S Baia; Alison L Slocum; Jeanette D Hyer; Anjan Misra; Nouzhan Sehati; Scott R VandenBerg; Burt G Feuerstein; Dennis F Deen; Michael W McDermott; Anita Lal
Journal:  J Neurooncol       Date:  2006-03-23       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.